Allergy Therapeutics plc
AGYTF News Today: Stay Updated with the Latest Allergy Therapeutics plc News in Real Time
Find AGYTF news now at Meyka AI. Stay informed with the latest Allergy Therapeutics plc stocks updates, including price news, market analysis, and expert insights.
^DJI Today, March 26: Middle East De-escalation Sparks Best Day Since Feb
Dow Jones today jumps on Middle East de-escalation, marking its best day since February. See drivers of the Dow rally, key levels, and how Australian investors can position into a potential stock mark
BTIG Maintained Buy on Aldeyra Therapeutics (ALDX) March 17, 2026
BTIG maintained Buy on Aldeyra; read our ALDX analyst rating summary and implications
Cowen Maintains AZN (AstraZeneca PLC) at Buy on March 18, 2026
Cowen maintains AZN at Buy on March 18, 2026; AZN analyst rating remains positive with Meyka grade A
Maintained to Buy for SW Smurfit Westrock Plc by Cowen & Co March 2026
Cowen & Co maintained Buy on Smurfit Westrock Plc; SW analyst rating reviewed March 2026
Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026
CTMX analyst rating: Jefferies maintains Buy and raises PT to $16. Read implications and Meyka AI grade B+
STSR stock $2.62 PNK: tested valuation with Meyka forecast and trading signals
STSR stock trades at $2.62 on PNK; analysis covers valuation, Meyka grade, and a 12-month forecast
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026
PTGX analyst rating: Jefferies and Johnson Rice maintain Buy March 2026 with price target updates and market context
UBS upgrades AU (AngloGold Ashanti Plc) to Buy March 2026
UBS upgrades AU to Buy on Mar 24, 2026. AU analyst rating change, market reaction, and investor implications
NMLSF (Nova Mentis Life Science Corp., PNK) $0.072 25 Mar 2026: check Meyka forecast
NMLSF stock jumps to $0.072 on volume; Meyka AI projects up to 114.93% in 12 months for this biotech microcap